A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])
Primary Objective
Dose Escalation: To assess safety and tolerability of escalating doses of MT-601. To determine the preliminary recommended phase 2 dose and schedule (RP2DS) Dose Expansion: To assess anti-tumor activity of MT-601 based on 2014 Lugano criteria or other disease specific response criteria
Details
Age
Adult
Locations
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
MANALI KAMDAR
Study ID
Protocol Number: 23-0056
More information available at ClinicalTrials.gov: NCT05798897
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers